Post Blogs, Photos, Youtube, Vimeo Videos, Topics, Events, Groups.
+ Larger Font | - Smaller Font

Welcome to Robins Social Network

Be part of the community and join us today!

More than 85 small molecule protein degraders are currently being evaluated for the treatment of various disease indications; in addition, there are over 25 technology platforms available for use in therapy development efforts

The concept of targeted protein degradation presents revolutionary drug development opportunities and is anticipated to bring about a paradigm shift in modern healthcare. The first targeted protein degrader, called proteolysis targeting chimera (PROTAC), was developed about a decade ago. Presently, a variety of other such chemical entities and molecular glues are under investigation. In fact, certain pipeline candidates are already in the mid to late-phase trials and are anticipated to soon enter the market.


To order this 330+ page report, which features 130+ figures and 145+ tables, please visit this link


The USD 3.6 billion (by 2030) financial opportunity within the target protein degradation market has been analyzed across the following segments:

§  Type of payment of licensing agreements

§  Upfront payments

§  Milestone payments


§  Type of protein degrader

§  Degronimids


§  SARDs / SERDs

§  Specific BET and DUB inhibitors

§  Other protein degraders


§  Therapeutic area

§  Neurodegenerative disorders

§  Oncological disorders

§  Other therapeutic areas


§  Route of administration  

§  Oral

§  Intravenous

§  Other routes


§  Key geographical region

§  North America

§  Europe

§  Asia-Pacific


The Targeted Protein Degradation Market: Focus on Therapeutics and Technology Platforms (based on Degronimids, ENDTACs, Epichaperome Inhibitors, Hydrophobic Tags, IMiDs, LYTACs, Molecular Glues, PHOTACs, PROTACs, Protein Homeostatic Modulators, SARDs, SERDs, SNIPERs, and Specific BET and DUB Inhibitors), 2020-2030report features the following companies, which we identified to be key players in this domain:

§  Arvinas

§  Captor Therapeutics

§  Celgene

§  Genetech

§  Kymera Therapeutics

§  Mission Therapeutics

§  Progenra

§  Radius Health 

§  Sanofi Genzyme

§  Zenopharm


Table of Contents


1. Preface

2. Executive Summary

3. Introduction

4. Current Market Landscape

5. Company Profiles

6. Clinical Trial Analysis 

7. KOL Analysis

8. Publication Analysis

9. Funding and Investment Analysis

10. Partnerships and Collaborations

11.  Market Sizing and Opportunity Analysis

12. Executive Insights


13. Concluding Remarks


14. Appendix 1: Tabulated Data


15. Appendix 2: List of Companies and Organizations


To purchase a copy, please visit


Contact Details

Gaurav Chaudhary

+1 (415) 800 3415


on January 4 at 10:09

Comments (0)

Become a member and experience a unique opportunity to post blogs, photos, Youtube Vimeo videos, topics, events, and create groups on Robin's Social Networking Site. Use Robin's Social to sell products, services and market your business when posting blogs.

By registering and posting content, you agree to the terms listed at... Posting Terms and Conditions. Enjoy!

© 2022 Content By Members. All Rights Reserved.